Navigation Links
Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
Date:5/23/2012

NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

http://www.reportlinker.com/p0866960/Arthritis-Therapeutics-Market-to-2018---Novel-Oral-JAK-Inhibitors-and-Biologic-Disease-Modifying-Anti-Rheumatic-Drugs-DMARD-Will-Drive-Continued-Growth-Across-Key-Indications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Summary GBI Research's new report, "Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications", provides an expert insight into the global arthritis market and market forecast until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the top four arthritis therapeutic indications which are osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape of the top companies in the market and an analysis of the key trends in mergers and acquisitions, and licensing agreements involving arthritis therapies.

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research analysis shows that the global arthritis therapeutics market was estimated at $20.6 billion in 2010, during the forecast period the market grow at a Compound Annual Growth Rate (CAGR) of 7.2% between 2010 and 2018 to a $38 billion. The market share of rheumatoid arthritis, osteoarthritis, psoriatic arthritis and ankylosing spondylitis in the overall arthritis market was 68%, 22%, 7.4% and 2.6%, respectively, in 2010. The rheumatoid arthritis market was $14 billion in 2010. The market revenue is expected to increase to $26.9 billion by 2018 at a CAGR of 8.5%. The osteoarthritis market is expected to show slower growth among the top four indications. Top six companies in the arthritis therapeutics market accounted for a share of close to 62% in 2010, leaving 38% of the market dominated by generic therapies and smaller players. Despite a significant number of products available on the market, the high value of biologics keeps the market value high.

GBI Research analysis shows that the Research and Development (R&D) pipeline for the arthritis therapeutics market is strong. The rich arthritis pipeline is likely to support the growth of this market thereby attracting many pharmaceutical and biotechnological companies. Major pharmaceutical companies such as Pfizer, Amgen, Merck, Roche and Novartis are already active in R&D for arthritis therapies.

Scope

- Data and analysis of the arthritis market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan. - Annualized market data for the osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis markets from 2004 to 2010, with forecasts to 2018.- Market Data on geographical landscape and therapeutic landscape including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.- Key drivers and restraints that have had a significant impact on the market - The competitive landscape of the arthritis market which includes companies such as Johnson & Johnson, Abbott, Amgen, Pfizer, Roche and Bristol-Myers Squibb.- Key M&A activities and licensing agreements that took place from 2005 to 2011 in the arthritis market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.- Device a more tailored country strategy by understanding the key drivers and barriers of the arthritis market.- Develop key strategic initiatives by understanding the key focus areas of the leading companies.- Accelerate and strengthen your market position by identifying the key companies for mergers, acquisitions and strategic partnerships.

Table of Contents

1 Table of Contents1 Table of Contents 61.1 List of Tables 91.2 List of Figures 112 Arthritis Therapeutics Market to 2018 - Introduction 123 Arthritis Therapeutics Market to 2018 - Market Overview 143.1 Introduction 143.2 Revenue Forecasts for the Global Arthritis Therapeutics Market 153.2.1 Revenue 153.2.2 Annual Cost of Treatment 163.3 Treatment Usage Patterns 173.3.1 Diseased Population 183.3.2 Treatment Seeking Population 183.3.3 Diagnosis Population 183.3.4 Prescription Population 194 Arthritis Therapeutics Market to 2018 - Therapeutic Landscape 204.1 Osteoarthritis Therapeutics Market 204.1.1 Introduction 204.1.2 Epidemiology 214.1.3 Symptoms 214.1.4 Diagnosis 214.1.5 Diagnostic Imaging Techniques 224.1.6 Treatment 224.1.7 Revenue 254.1.8 Annual Cost of Treatment 264.1.9 Treatment Usage Patterns 274.1.10 Marketed Products 294.2 Drivers and Barriers for the Osteoarthritis Therapeutics Market 304.2.1 Drivers for the Osteoarthritis Therapeutics Market 304.2.2 Barriers for the Osteoarthritis Therapeutics Market 304.3 Opportunity and Unmet Need 314.4 Arthritis Therapeutics Market 324.4.1 Introduction 324.4.2 Epidemiology 334.4.3 Symptoms 334.4.4 Diagnosis 344.4.5 Diagnostic Techniques 344.4.6 Treatment 354.4.7 Non-Pharmacological Therapy 364.4.8 Surgical Treatment 364.4.9 Pharmacological Therapy 364.4.10 Revenue 374.4.11 Annual Cost of Treatment 384.4.12 Treatment Usage Patterns 394.4.13 Marketed products 414.5 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 424.5.1 Drivers for the Rheumatoid Arthritis Therapeutics Market 424.5.2 Barriers for the Rheumatoid Arthritis Therapeutics Market 424.6 Opportunity and Unmet Needs 434.7 Psoriatic Arthritis Therapeutics Market 434.7.1 Introduction 434.7.2 Epidemiology 444.7.3 Symptoms 444.7.4 Diagnosis 444.7.5 Diagnostic Techniques 444.7.6 Treatment 454.7.7 Non-Pharmacological Therapy 454.7.8 Pharmacological Therapy 454.7.9 Surgery 464.7.10 Revenue 464.7.11 Annual Cost of Treatment 474.7.12 Treatment Usage Patterns 484.7.13 Marketed Products 504.8 Drivers and Barriers for the Psoriatic Arthritis Therapeutics Market 514.8.1 Drivers for the Psoriatic Arthritis Therapeutics Market 514.8.2 Barriers for the Psoriatic Arthritis Therapeutics Market 514.9 Opportunity and Unmet Needs 514.10 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Market 524.10.1 Introduction 524.10.2 Epidemiology 524.10.3 Symptoms 534.10.4 Diagnosis 534.10.5 Treatment 544.10.6 Non-Pharmacological Therapy 544.10.7 Pharmacological Therapy 554.10.8 Surgery 564.10.9 Revenue 564.10.10 Annual Cost of Treatment 574.10.11 Treatment Usage Patterns 584.10.12 Marketed products 604.11 Drivers and Barriers for the Ankylosing Spondylitis Therapeutics Market 604.11.1 Drivers for the Ankylosing Spondylitis Therapeutics Market 604.11.2 Barriers for the Ankylosing Spondylitis Therapeutics Market 604.12 Opportunity and Unmet Need 615 Arthritis Therapeutics Market to 2018 - Geographical Landscape 625.1 Revenue Analysis by Geography 625.2 The US 635.2.1 Revenue 635.2.2 Annual Cost of Treatment 655.2.3 Treatment Usage Patterns 665.3 Top Five European countries (UK, Germany, France, Italy and Spain) 685.3.1 Revenue 685.3.2 Annual Cost of Treatment 695.3.3 Treatment Usage Patterns 705.4 Japan 725.4.1 Revenue 725.4.2 Annual Cost of Treatment 735.4.3 Treatment Usage Patterns 746 Arthritis Therapeutics Market to 2018 - Product Pipeline Analysis 766.1 Introduction 786.1.1 Research and Development Pipeline – Osteoarthritis 786.2 Introduction 836.2.1 Research and Development Pipeline – Rheumatoid Arthritis 836.3 Introduction 956.3.1 Research and Development Pipeline – Psoriasis Arthritis 956.4 Introduction 966.4.1 Research and Development Pipeline – Ankylosing Spondylitis 966.5 Profiles of Promising Drugs in the Pipeline 986.5.1 Tofacitinib (CP-690550) 986.5.2 Ofatumumab 996.5.3 Secukinumab (AIN457) 996.5.4 Fostamatinib (R788) 1006.5.5 LY2127399 (Tabalumab) 1016.5.6 REGN88 (SAR153191) 1026.5.7 LT-NS001 1037 Arthritis Therapeutics Market to 2018 - Competitive Landscape 1047.1 Market Share Analysis 1047.1.1 Major Players 1047.2 Competitive Profile 1057.2.1 Roche 1057.2.2 Johnson & Johnson 1077.2.3 Pfizer 1087.2.4 Abbott Laboratories 1107.2.5 Bristol-Myers Squibb 1117.2.6 Amgen 1128 Arthritis Therapeutics Market to 2018 - Strategic Consolidations 1138.1 Mergers and Acquisitions 1138.1.1 Overview 1138.1.2 Major Merger and Acquisition Deals 1138.1.3 Possible Future Merger and Acquisition Deals 1198.2 Licensing Agreements 1208.2.1 Overview 1208.2.2 Major Licensing Deal 1208.3 Co-Development Agreements 1268.4 Deals by Geography 1328.5 Deals by Value 1339 Arthritis Therapeutics Market to 2018 - Appendix 1349.1 Market Definitions 1349.2 Abbreviations 1349.3 Sources 1359.4 Research Methodology 1369.4.1 Coverage 1369.4.2 Secondary Research 1369.4.3 Primary Research 1379.4.4 Forecasts 1379.4.5 Expert Panel Validation 1409.5 Contact Us 1409.6 Disclaimer 140

List of Tables

1.1 List of TablesTable 1: Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 15Table 2: Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 16Table 3: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 16Table 4: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 17Table 5: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 17Table 6: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 18Table 7 : Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 25Table 8: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 26Table 9: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 26Table 10: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 26Table 11: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 27Table 12: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 28Table 13: Osteoarthritis Therapeutics Market, Marketed Products, 2010 29Table 14: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 37Table 15: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 37Table 16: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 38Table 17: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 38Table 18: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 39Table 19: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 40Table 20: Rheumatoid Arthritis Therapeutics-Marketed Products, 2010 41Table 21: Psoriatic Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 47Table 22: Psoriatic Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 47Table 23: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 47Table 24: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 48Table 25: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 49Table 26: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 49Table 27: Psoriatic Arthritis Therapeutics-Marketed Products, 2010 50Table 28: Ankylosing Spondylitis Therapeutics Market, Global, Revenue ($m), 2004-2010 56Table 29: Ankylosing Spondylitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018 56Table 30: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 57Table 31: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 57Table 32: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 58Table 33: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 59Table 34: Ankylosing Spondylitis Therapeutics-Marketed Products, 2010 60Table 35: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2004-2010 63Table 36: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2018 63Table 37: Arthritis Therapeutics Market, The US, Revenue ($bn), 2004-2010 64Table 38: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2018 64Table 39: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2004-2010 65Table 40: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2010-2018 65Table 41: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2010 66Table 42: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2018 66Table 43: Arthritis Therapeutics Market, Top Five EU Countries, Revenue ($bn), 2004-2010 68Table 44: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2010-2018 68Table 45: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2010 69Table 46: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2010-2018 69Table 47: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2010 70Table 48: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2010-2018 71Table 49: Arthritis Therapeutics Market, Japan, Revenue ($bn), 2004-2010 72Table 50: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2010-2018 72Table 51: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2010 73Table 52: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2018 73Table 53: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2010 74Table 54: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2018 74Table 55: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 79Table 56: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 80Table 57: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Develoment Stage Molecules, 2011 80Table 58: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 81Table 59: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 82Table 60: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 82Table 61: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 84Table 62: Arthritis Therapeutics Market, Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 85Table 63: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 86Table 64: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 87Table 65: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 88Table 66: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 89Table 67: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 90Table 68: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 92Table 69: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 93Table 70: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 94Table 71: Arthritis Therapeutics Market-Psoriatic Arthritis Pipeline, Development Stage Molecules, 2011 95Table 72: Arthritis Therapeutics Market-Psoriatic Arthritis Pipeline, Development Stage Molecules, 2011 96Table 73: Arthritis Therapeutics Market- Ankylosing Spondylitis Pipeline, Development Stage Molecules, 2011 97

List of Figures

1.2 List of FiguresFigure 1: Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 15Figure 2: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 16Figure 3: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 17Figure 4: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 25Figure 5: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 26Figure 6: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 27Figure 7: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 37Figure 8: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 38Figure 9: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 39Figure 10: Psoriatic Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 46Figure 11: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 47Figure 12: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 48Figure 13: Ankylosing Spondylitis Therapeutics Market, Global, Revenue Forecasts ($m), 2004-2018 56Figure 14: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 57Figure 15: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 58Figure 16: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2004-2018 62Figure 17: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2004-2018 64Figure 18: Arthritis Therapeutics Market, The US, Annual Cost of Treatment ($), 2004-2018 65Figure 19: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2018 66Figure 20: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2004-2018 68Figure 21: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2018 69Figure 22: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2018 70Figure 23: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2004-2018 72Figure 24: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2018 73Figure 25:Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2018 74Figure 26:Arthritis Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011 76Figure 27: Arthritis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 77Figure 28: Arthritis Therapeutics Market, Osteoarthritis Therapeutics, Global R&D Pipeline by Phase (%), 2011 78Figure 29: Arthritis Therapeutics Market-Rheumatoid Arthritis, Global R&D Pipeline by Phase (%), 2011 83Figure 30: Arthritis Therapeutics Market-Psoriatic Arthritis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 95Figure 31:Arthritis Therapeutics Market, Ankylosing Spondylitis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 96Figure 32:Arthritis Therapeutics Market, Global, Market Share of Top Six Companies (%), 2010 104Figure 33:Arthritis Therapeutics Market, SWOT Analysis, Roche, 2011 106Figure 34: Arthritis Therapeutics Market, SWOT Analysis, Johnson and Johnson Inc., 2011 107Figure 35: Arthritis Therapeutics Market, SWOT Analysis, Pfizer, 2011 109Figure 36: Arthritis Therapeutics Market, SWOT Analysis, Abbott Laboratories, 2011 110Figure 37: Arthritis Therapeutics Market, SWOT Analysis, Bristol-Myers Squibb, 2011 111Figure 38: Arthritis Therapeutics Market, SWOT Analysis, Amgen, 2011 112Figure 39: Arthritis Therapeutics Market, Global, Major Licensing Agreements By Geography, 2009-2011 132Figure 40: Arthritis Therapeutics Market, Global, Major Licensing Agreements by Value (%), 2009-2011 133Figure 41: GBI Research Market Forecasting Model 139

Companies Mentioned

RocheJohnson & JohnsonPfizerAbbott LaboratoriesBristol-Myers SquibbAmgen

To order this report:Therapy Industry: Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. The Strong Womans Approach to Managing Rheumatoid Arthritis
3. Defect in A20 gene expression causes rheumatoid arthritis
4. Hospital for Special Surgery to Host International Arthritis Summit: Frontiers in Osteoarthritis Research, Prevention and Care
5. CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis
6. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
7. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
8. Novel ACR Hybrid Score in Rheumatoid Arthritis Applied for the First Time to Data from the RAPID 1 Study with Cimzia® (certolizumab pegol)
9. Arthritis drug could help beat melanoma skin cancer
10. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
11. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... -- On Thursday, February 11, 2-1-1 San Diego ... and disaster services, and the Community Information Exchange ... coordination and service delivery for the community to better ... better connect service providers to the information they can ... has handled more than 2.5 million connections ...
(Date:2/5/2016)... 5, 2016 Amarantus BioScience Holdings, ... focused on developing products for Regenerative Medicine, Neurology and ... Disease Designation (RPDD) from the US Food and Drug ... MANF was previously granted orphan drug designation (ODD) by ... Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), ...
(Date:2/5/2016)... Feb. 5, 2016 Australian-US drug discovery and development ... the appointment of a new Chairman, Mr John O,Connor ... effective immediately. James Garner , has also ... and former Acting CEO, Mr Iain Ross , will ... --> James Garner , has also been formally ...
(Date:2/4/2016)... San Francisco, CA (PRWEB) , ... February 04, ... ... future of enterprise talent development and compliance training, today announced an interactive ... on Morf Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course ...
Breaking Biology Technology:
(Date:2/5/2016)... 2016 http://www.researchandmarkets.com/research/5kvw8m/global_facial ) ... "Global Facial Recognition Market 2016-2020" report ... ) has announced the addition of the ... report to their offering. --> ... announced the addition of the "Global ...
(Date:2/4/2016)... -- The field of Human Microbiome research and ... hubs of the biotechnology industry. While the Human ... human microbiota, have garnered a lot of attention ... has literally exploded in terms of both basic ... on biomedical aspects of research, development, and commercial ...
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... compared with fourth quarter of 2014. Gross margin was 46% ... Earnings per share increased to SEK 6.39 (loss: 0.49). ... , --> --> January ... (233.6), up 1,142% compared with 2014. Gross margin was 43% ...
Breaking Biology News(10 mins):